Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,734 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,061 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | terminated | N/A | 21 | University Hospital HeidelbergOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03099265 | Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Yale UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02822716 | Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy(IRE) | terminated | N/A | 11 | Chinese University of Hong KongOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | terminated | Phase 2 | 17 | Delcath Systems Inc.INDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03827044 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer(POLEM) | terminated | Phase 3 | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01665274 | Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer(repeat) | terminated | Phase 2 | 15 | Harbin Medical UniversityOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04372992 | The Stoma Closure Before or After Adjuvant Therapy Trial(STOMAD) | terminated | N/A | 14 | Ospedale Umberto I di TorinoOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05018325 | Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy | terminated | N/A | 32 | Washington University School of MedicineOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03172403 | Skeletal Muscle Expression of Myostatin and Cancer of Digestive System Associated Cachexia(MYOCAC) | terminated | N/A | 3 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | terminated | Phase 1 | 2 | Eureka Therapeutics Inc.INDUSTRY | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT01862718 | Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Aug 15, 2022 | clinicaltrials |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | terminated | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02960282 | Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy | terminated | — | 21 | University of Southern CaliforniaOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT03287947 | LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | terminated | Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02681601 | Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer(RITCOLON) | terminated | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | terminated | N/A | 8 | Wright State UniversityOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | terminated | Phase 2 | 1 | BTG International Inc.OTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | terminated | N/A | 12 | Duke UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02445456 | Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer(SentiRect) | terminated | N/A | 15 | Oxford University Hospitals NHS TrustOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | terminated | N/A | 70 | University of WashingtonOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT01759238 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer(OLGA) | terminated | Phase 2 | 1 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection(PATRON) | terminated | Phase 3 | 520 | Cellxpert Biotechnology Corp.INDUSTRY | 4 | Jun 23, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | terminated | N/A | 18 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02503111 | The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men(HPV-SAVE) | terminated | N/A | 71 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03970694 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer | terminated | Phase 3 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients(PGPC1) | terminated | Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | terminated | Phase 1 | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04187937 | Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections | terminated | N/A | 1 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04176952 | PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer(PRIMUS002) | terminated | Phase 2 | 31 | Judith Dixon-HughesOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | terminated | Phase 2 | 3 | AIO-Studien-gGmbHOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT03475680 | Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery(COLONPREP) | terminated | Phase 3 | 193 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | terminated | Phase 2 | 154 | MorphotekINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Nov 3, 2022source: clinicaltrials